While the 23andMe acquisition isn't a reason to buy Regeneron, the stock's recently depressed price makes it worth a closer look. The company's former top-selling treatment, Eylea, is losing ...

Regeneron's bid to acquire the bankrupt genetic testing firm 23andMe for $256 million has likely come to an end.

SALT LAKE CITY (KUTV) — Utah families who used 23andMe's genetic testing services face unique privacy risks as the biotech company enters bankruptcy proceedings and prepares for sale to pharmaceutical ...

A bankruptcy court approved the $305M sale of 23andMe to a nonprofit led by Anne Wojcicki, raising questions about data ...

Anne Wojcicki, founder and former CEO of 23andMe, will helm the company again after her nonprofit's purchase was approved.

Genetic testing company 23andMe can proceed with a $305 million sale to the company’s co-founder Anne Wojcicki after a U.S.

Healthcare mergers and acquisitions are in no short supply as providers, health tech companies, retailers and other industry ...

A bankruptcy court this week approved the $305 million sale of genetics testing firm 23andMe to a nonprofit organization led ...

Anne Wojcicki’s bid to buy 23andMe, the genetic testing company she co-founded nearly 20 years ago, has received the court ...

Regeneron Pharmaceuticals has declined to submit a new bid for genetic testing company 23andMe exceeding its original winning bid of $256 million, a company spokesperson told Reuters on Monday.

While the 23andMe acquisition isn't a reason to buy Regeneron, the stock's recently depressed price makes it worth a closer look. The company's former top-selling treatment, Eylea, is losing ...

A bankruptcy judge approved the sale of 23andMe's assets and business operations to a nonprofit led by 23andMe’s co-founder ...